International Journal of Pancreatology

, Volume 4, Issue 4, pp 363–369 | Cite as

Androgen influence on exocrine pancreatic cancer

  • Å Andrén-Sandberg


Since the discovery of the first gastrointestinal hormones it has been intriguing to think that these defined chemical messengers may also influence the growth of tumors. Today, treatment with sex-hormones is well documented—and used in clinical practice—in prostatic (1,2), breast (3), endo-metrial, and ovarian carcinoma(4). Hormonal therapy (progesterone) has also been tried with some success in renal carcinoma(5,6). Nevertheless, cancers of the gastrointestinal tract—colorectal, liver, stomach, and pancreatic carcinoma, which constitute 25 percent of all malignancies in Scandinavia—are only treated by other means, mainly surgery, although there is substantial evidence today that these tumors can also be influenced by hormones.

Key Words

Hormones pancreas cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Torti FM. Hormonal therapy for prostate cancer. New Engl. J. Med. 1984; 311: 1313- 1318.PubMedGoogle Scholar
  2. 2.
    Waxman J. Hormonal aspects of prostatic cancer: A review. J. Royal Soc. Med. 1985; 78: 129–1316.Google Scholar
  3. 3.
    Hubay CA, Arafah B, Gordon NH, Guyton SP, Crowe JP. Hormone receptors. An update and application. Surg. Clin. North Am. 1984; 64: 1155–1168.PubMedGoogle Scholar
  4. 4.
    Kauppila A. Protestin therapy of endometrial, breast and ovarial carcinoma. A review of clinical observations. Acta Obstet. Gynecol. Scand. 1984; 63: 441–448.PubMedCrossRefGoogle Scholar
  5. 5.
    Mukamel E, Bruhis S, Nissenkorn I, Servadio C. Steroid receptors in renal cell carcinoma: Relevance to hormonal therapy. J. Urol. 1984; 131: 227–233.PubMedGoogle Scholar
  6. 6.
    Nakano E, Tada Y, Fujioka H, Matsuda M, Osafune M, Kotake T, Sato B, Takaha M, Soneda T. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J. Urol. 1984; 132: 240–246.PubMedGoogle Scholar
  7. 7.
    Grieg RG, Schein PS. Therapy of gastrointestinal cancer, In: Polak, Bloom, Wright, Butler (Eds.), Basic science in gastroenterology. Diseases of the gut, United Kingdoms: Glaxo group research limited. Hearts, 1986: 329–336.Google Scholar
  8. 8.
    Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and the prostate, J. Steroid Biochem. 1979; 11: 293–299.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandberg AA, Kirdany RY, Varkarakis MJ, Murphy GP. Estrogen receptor protein in pancreas. Steroids 1973; 22: 259–271.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenthal HE, Sandberg AA. Estrogen binding proteins in rat pancreas. J. Steroid Biochem. 1978; 9: 1133–1139.PubMedCrossRefGoogle Scholar
  11. 11.
    Andrén-Sandberg Å. Estrogens and pancreatic cancer. Some recent aspects. Scand. J. Gastroenterol. 1986; 21: 129–135.PubMedCrossRefGoogle Scholar
  12. 12.
    Greenway BA. Carcinoma of the exocrine pancreas: A sex hormone responsive tumour? Br. J. Surg. 1987; 74: 441–442.PubMedCrossRefGoogle Scholar
  13. 13.
    Boctor AM, Band P, and Grossman A. Requirement for an accessory factor for binding of (3H)estradiol to protein to the cytosol fraction of rat pancreas. Proc. Natl. Acad. Sci. USA 1981; 78: 5648–5652.PubMedCrossRefGoogle Scholar
  14. 14.
    Band P, Richardson SB, Boctor AM, Grossman A. Somatostatin enhances binding of (3H)estradiol to a cytosolic protein in rat pancreas. Possible role of oligopeptide coligands in secretions. J. Biol. Chem. 1983; 258: 7284–7287.PubMedGoogle Scholar
  15. 15.
    Pousette Å. Demonstration of an androgen receptor in rat pancreas. Biochem. J. 1976; 157: 229–234.PubMedGoogle Scholar
  16. 16.
    Lhoste EF, Roebuck BD, Stern JE, Longnecker DS. Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat. Pancreas 1987; 2: 38–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenway B, Iqbal MJ, Johnson PJ, Williams R. Low serum testosterone concentrations in patients with carcinoma of the pancreas. Br. Med. J. 1983; 286: 93–95.CrossRefGoogle Scholar
  18. 18.
    Militello C, Sperti C, Foresta C. Plasma levels of testosterone and hypophyseal gonadotropins in men affected by pancreatic cancer. Digestion 1984; 30: 122.Google Scholar
  19. 19.
    Shearer MG, Taggart D, Gray C, Imrie CW. Useful differentiation between pancreatic carcinoma and chronic pancreatitis by testosterone assay. Digestion 1984; 30: 106.Google Scholar
  20. 20.
    Gonzalez-Barcena D, Rangel-Garcia NE, Perez-Sanchez PL, Guttierrez-Damperio C, Garcia-Carrasco F, Comaru-Schally AM, Schally AV. Response to D-TRP-6 LH-RH in advanced adenocarcinoma of pancreas. Lancet 1986; ii (8499): 154.CrossRefGoogle Scholar
  21. 21.
    Schally AV, Comaru-Schally AM, Redding TW. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med. 1984; 175: 259–281.PubMedGoogle Scholar
  22. 22.
    Pasquali C, Marra S, Scandellari C, Pedrazzoli P. Testosterone and hypophyseal gonadotropin plasma levels in men affected by pancreatic cancer. Ital. J. Gastroenterol. 1985; 17: 56.Google Scholar
  23. 23.
    Greenway B, Iqbal MJ, Johnson PJ, Williams R. Serum sex-steroid concentrations in patients with pancreatic carcinoma. Br. J. Surg. 1982; 69: 293–296.Google Scholar
  24. 24.
    Robles-Diaz G, Diaz V, Ornelas R, Mendez JP, Wolpert E. Testosterone:Dihydrotestosterone ratio, a new tumor marker in pancreatic cancer. Dig. Dis. Sci. 1986; 31: 68S.CrossRefGoogle Scholar
  25. 25.
    Greenway B, Duke D, Pym B. A control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br. J. Surg. 1982; 69: 595–000.PubMedCrossRefGoogle Scholar
  26. 26.
    Longnecker DS. The azaserine-induced model of pancreatic carcinogenesis in rats. In: Scarpelli DG, Reddy JK, Longnecher DS, Eds., Experimental pancreatic carcinogenesis. Boca Raton, CRC Press Inc., 1986: 117–130.Google Scholar
  27. 27.
    Lhoste EF, Roebuck BD, Brinck-Johnsen T, Longnecker DS. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Ficher rats. Carcinogenesis 1987; 8: 699–703.PubMedCrossRefGoogle Scholar
  28. 28.
    Hayashi Y, Katayama H. Promoting effect of testosterone propionate on experimental exocrine pancreatic tumors by 4-Hydroxyaminoquinoline-l-oxide in rats. Toxicol. Lett. 1981; 9: 349–356.PubMedCrossRefGoogle Scholar
  29. 29.
    Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. 1986; 46: 2276–2281.PubMedGoogle Scholar
  30. 30.
    Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA 1984; 81, 248–252.PubMedCrossRefGoogle Scholar
  31. 31.
    Paz-Bouza JI, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analoges of somatostatine and luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 1987; 84, 1112–1116.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • Å Andrén-Sandberg
    • 1
  1. 1.Department of SurgeryLund UniversityLundSweden

Personalised recommendations